Fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, blocks steatosis and alters the inflammatory response in a mouse model of inflammation-dioxin interaction
- PMID: 34052195
- DOI: 10.1016/j.cbi.2021.109521
Fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, blocks steatosis and alters the inflammatory response in a mouse model of inflammation-dioxin interaction
Abstract
2,3,7,8-Tetrachlorodibenzo-p-dioxin (dioxin; TCDD) is an environmental contaminant that elicits a variety of toxic effects, many of which are mediated through activation of the aryl hydrocarbon receptor (AhR). Interaction between AhR and the peroxisome proliferator-activated receptor-alpha (PPAR-α), which regulates fatty acid metabolism, has been suggested. Furthermore, with recognition of the prevalence of inflammatory conditions, there is current interest in the potential for inflammatory stress to modulate the response to environmental agents. The aim of this work was to assess the interaction of TCDD with hepatic inflammation modulated by fenofibrate, a PPAR-α agonist. Female, C57BL/6 mice were treated orally with vehicle or fenofibrate (250 mg/kg) for 13 days, and then were given vehicle or 30 μg/kg TCDD. Four days later, the animals received an i.p. injection of lipopolysaccharide-galactosamine (LPS-GalN) (0.05x107 EU/kg and 500 mg/kg, respectively) to incite inflammation, or saline as vehicle control. After 4 h, the mice were euthanized, and blood and liver samples were collected for analysis. Livers of animals treated with TCDD with or without LPS-GalN had increased lipid deposition, and this effect was blocked by fenofibrate. In TCDD/LPS-GalN-treated mice, fenofibrate caused an increase in plasma activity of alanine aminotransferase, a marker of hepatocellular injury. TCDD reduced LPS-GalN-induced apoptosis, an effect that was prevented by fenofibrate pretreatment. LPS-GalN induced an increase in the concentration of interleukin-6 in plasma and accumulation of neutrophils in liver. TCDD exposure enhanced the former response and inhibited the latter one. These results suggest that fenofibrate counteracts the changes in lipid metabolism induced by TCDD but increases inflammation and liver injury in this model of inflammation-TCDD interaction.
Keywords: Apoptosis; Il-6; Inflammation; Liver; PPAR; TNF.
Copyright © 2021 Elsevier B.V. All rights reserved.
Similar articles
-
Anti-inflammatory role of fenofibrate in treating diseases.Biomol Biomed. 2023 May 1;23(3):376-391. doi: 10.17305/bb.2022.8534. Biomol Biomed. 2023. PMID: 36724021 Free PMC article. Review.
-
Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1573-9. doi: 10.1161/ATVBAHA.110.220525. Epub 2011 Apr 7. Arterioscler Thromb Vasc Biol. 2011. PMID: 21474829 Free PMC article.
-
[Protective effect of glycogen synthase kinase 3β inhibition via peroxisome proliferator-activated receptor alpha activation in mice with acute liver failure].Zhonghua Gan Zang Bing Za Zhi. 2017 Mar 20;25(3):211-216. doi: 10.3760/cma.j.issn.1007-3418.2017.03.010. Zhonghua Gan Zang Bing Za Zhi. 2017. PMID: 28482409 Chinese.
-
Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.Liver Int. 2006 Jun;26(5):613-20. doi: 10.1111/j.1478-3231.2006.01265.x. Liver Int. 2006. PMID: 16762007
-
Role of the PPAR-α agonist fenofibrate in severe pediatric burn.Burns. 2012 Jun;38(4):481-6. doi: 10.1016/j.burns.2011.12.004. Epub 2012 Jan 9. Burns. 2012. PMID: 22226866 Free PMC article. Review.
Cited by
-
Anti-inflammatory role of fenofibrate in treating diseases.Biomol Biomed. 2023 May 1;23(3):376-391. doi: 10.17305/bb.2022.8534. Biomol Biomed. 2023. PMID: 36724021 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources